United States Patent 12,016,875 (Claims Scope) and Its US Landscape
US Patent 12,016,875 claims a monthly intravitreal dosing method for geographic atrophy (GA) using a pegylated aptamer defined by a specific nucleotide chemistry and sequence (SEQ ID NO: 26), at a fixed dose of 2 mg/eye.
What does the patent claim, at the method level?
Independent claim 1: core treatment method
Claim 1 is framed as a method of treating geographic atrophy in a human subject. It is not a composition-only claim; it is a dosing-and-outcome claim.
Claim 1 elements (all must be met):
- Condition / target: “treating geographic atrophy in a human subject.”
- Route: intravitreal injection.
- Dose: 2 mg/eye of a pegylated aptamer.
- Dosing frequency: “monthly.”
- Aptamer identity: the pegylated aptamer comprises a sequence:
- fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfU mGmAmGfUfUfUAfCfCfUmGfCmG-3T (SEQ ID NO: 26)
- Nucleotide chemistry constraints (define the chemical modifications across the sequence):
- fC and fU are 2’-fluoro nucleotides
- mG and mA are 2’-OMe nucleotides
- all other nucleotides are 2’-OH
- “3T” is an inverted deoxythymidine
- or a salt of that modified aptamer
- Pegylation constraint: “the pegylated moiety has the following structure” (structure is referenced but not reproduced in the excerpt).
- Functional effect / limitation: the method “slows or inhibits loss of visual acuity.”
Practical scope takeaway: In US litigation and licensing, Claim 1 typically becomes the “center of gravity.” Any competitor must avoid all of the following simultaneously:
- monthly intravitreal administration to GA
- 2 mg/eye
- a pegylated aptamer with the defined modified-nucleotide scheme and sequence
- and the claimed visual acuity effect framing (though this is usually litigated via experimental proof, not subjective intent)
Claim 2–3: formulation tightening
Claim 2 adds formulation detail.
Claim 2 elements:
- aqueous solution
- plus one or more pH buffering agents
- plus at least one tonicity adjuster
Claim 3 further specifies:
- pH buffers: dibasic sodium phosphate heptahydrate and monobasic sodium phosphate monohydrate
- tonicity adjuster: sodium chloride
Practical scope takeaway: Claims 2–3 narrow coverage to a specific buffered isotonic formulation. They usually matter most for knock-out freedom-to-operate (FTO) evaluations of manufacturing/formulation and for asserting narrower infringement theories.
Claims 4–10: visual acuity endpoints and timing
Claims 4–10 attach the claimed effect to specific clinical readouts.
Claim 4: slowing/inhibiting the decrease in BCVA vs non-treated.
Claim 5: increases BCVA vs non-treated.
Claims 6–9: define measurement windows (at least or about):
- 1 month (baseline to ≥1 month)
- 6 months
- 8 months
- 12 months
Claim 10: BCVA measured using ETDRS letters.
Practical scope takeaway: These claims provide more concrete infringement anchors: if clinical data use ETDRS letters and analyze changes over those time windows, the evidence match becomes tighter.
How broad is Claim 1 in the real world?
Aptamer identity is the main narrowing lever
Claim 1 hard-wires:
- a specific sequence (SEQ ID NO: 26)
- specific modification types (2’-fluoro, 2’-OMe, otherwise 2’-OH)
- a defined terminal modification (inverted deoxythymidine as “3T”)
- and “pegylated moiety” structure (not fully displayed in your excerpt but treated as a structural limitation)
This makes the claim highly sequence- and chemistry-specific. A competitor using:
- a different aptamer sequence,
- different modification pattern,
- or different pegylation architecture,
can avoid literal coverage even if the therapeutic concept (GA intravitreal monthly aptamer) is similar.
Dose and regimen are also limiting
Claim 1 requires:
- 2 mg/eye
- intravitreal
- monthly
So dosing at 1 mg/eye, 3 mg/eye, different injection intervals, or different eye administration cadence can create design-around space, at least from a literal infringement standpoint.
Outcome language adds an evidentiary frame
“Slows or inhibits loss of visual acuity” is a functional limitation. Courts generally require proof that the accused method achieves the claimed functional outcome in the relevant patient population, using the claim’s definitions where applicable (BCVA, ETDRS, time windows in dependent claims).
What does the claim set imply about US patent family coverage?
Based on the claim structure, the family (or at least this granted US asset) likely covers at least three layers:
-
Core method with defined aptamer chemistry and dose/regimen
-
Formulation claims for buffering and tonicity control
-
Clinical endpoint/time window framing
If there are continuation filings, they typically extend coverage by:
- alternative dose levels
- alternative dosing frequencies
- different endpoints (safety, lesion metrics, functional vision outcomes)
- formulation variations
- additional aptamer variants (though Claim 1’s SEQ ID: 26 constraint suggests variant space may be handled via separate families)
How strong is the claim set against generic design-around strategies?
Below are common design-around approaches and how they intersect with Claim 1.
| Design-around tactic |
Direct interaction with Claim 1 |
Likely effect |
| Use a different aptamer sequence |
Claim 1 requires SEQ ID NO: 26 |
Avoids literal aptamer identity |
| Keep sequence but change chemical modifications |
Claim 1 requires fC/fU=2’-F and mG/mA=2’-OMe with others 2’-OH |
Avoids literal chemistry |
| Keep chemistry but change pegylation structure |
Claim 1 requires a defined pegylated moiety structure |
Avoids literal pegylation |
| Change route (e.g., topical, systemic) |
Claim 1 requires intravitreal injection |
Avoids literal route |
| Change dose (not 2 mg/eye) |
Claim 1 requires 2 mg/eye |
Avoids literal dose |
| Change regimen (not monthly) |
Claim 1 requires monthly administration |
Avoids literal regimen |
| Use same method but dispute functional outcome proof |
Outcome limitation in Claim 1 |
Shifts to evidence/clinical proof issues |
What is the likely infringement map for competitors?
For a likely infringement theory under Claim 1, a plaintiff would typically align:
- a GA patient cohort
- treated with intravitreal injections at 2 mg/eye monthly
- receiving a pegylated aptamer whose chemical identity matches the defined modified sequence and pegylation moiety
- with clinical data supporting visual acuity slowing or inhibition
For dependent claims 2–3, the plaintiff would also tie:
- product formulation components
- buffer identities and tonicity agents
For dependent claims 4–10, plaintiff would tie:
- BCVA measurement via ETDRS
- baseline-to-1/6/8/12 month windows
What is the US patent landscape around this claim set?
Your excerpt provides Claim 1–10 but does not include:
- the patent’s assignee(s)
- application number(s)
- priority date(s)
- related US publication numbers
- cited references
- prosecution history (continuations, IDS, claim amendments)
Under your constraint set, that prevents a complete, verifiable landscape map (competitor patents, expected expiration timing, claim-to-claim overlaps, and design-around positions) for “US patent landscape” beyond the internal scope of 12,016,875 itself.
Accordingly, the only robust “landscape” content that can be produced accurately from the information provided is claim-bounded coverage and the design-around sensitivity derived directly from the limitations.
Key claim scope signals for freedom-to-operate (FTO)
These limitations are the highest-impact FTO levers because they are objective and structural:
- Aptamer sequence and ID: must match SEQ ID NO: 26 exactly as written in the claim.
- Modification pattern: requires fC/fU=2’-fluoro, mG/mA=2’-OMe, and the rest 2’-OH.
- Terminal modification: “3T” as inverted deoxythymidine.
- Pegylation: the claim references a structural pegylated moiety.
- Dose/regimen: 2 mg/eye and monthly intravitreal injections.
- Endpoint framing: ETDRS BCVA and timing windows in dependent claims 5–10.
Key Takeaways
- US 12,016,875 claims a GA treatment method using a specific pegylated aptamer defined by SEQ ID NO: 26 plus a defined nucleotide modification scheme (2’-F, 2’-OMe, and remaining 2’-OH) and inverted deoxythymidine terminal “3T.”
- The method is tightly bounded to intravitreal dosing at 2 mg/eye monthly and to a functional outcome of slowing or inhibiting visual acuity loss.
- Dependent claims narrow to specific buffered isotonic aqueous formulation (dibasic/monobasic sodium phosphate species and NaCl) and tie clinical readouts to ETDRS BCVA over 1, 6, 8, and 12 month windows.
FAQs
1) Is 12,016,875 a composition patent or a method patent?
It is a method of treating GA claim, defined by intravitreal injection, 2 mg/eye, monthly dosing, and the claimed pegylated aptamer identity.
2) What is the single most important design-around lever?
Changing the aptamer identity (sequence, modification pattern, pegylation architecture, or terminal “3T” inversion) because Claim 1 hard-wires SEQ ID NO: 26 and specific nucleotide chemistries.
3) Does the patent require showing benefit in ETDRS letters?
ETDRS is required in dependent Claim 10, and visual acuity timing windows are in dependent claims 6–9. Independent Claim 1 frames a “slows or inhibits loss of visual acuity” functional limitation.
4) Are formulation claims limited to specific excipients?
Yes. Dependent Claims 2–3 require an aqueous solution with dibasic sodium phosphate heptahydrate + monobasic sodium phosphate monohydrate and sodium chloride as tonicity adjuster.
5) What dosing parameters are explicitly claimed?
Intravitreal injection at 2 mg per eye with monthly administration.
References
[1] United States Patent 12,016,875 (claims 1–10 as provided in the prompt).
